Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 15, Issue 3, 2002, Pages 226-231

  Tsuchiya, Y ^a   Onda, M ^a   Sasajima, K ^a   Yamashita, K ^a   Nomura, T ^a   Makino, H ^a   Maruyama, H ^a   Hagiwara, N ^a   Takubo, K ^b   Miyashita, Masao ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ESOPHAGUS; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036918379     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.2002.00260.x     Document Type: Article

References (31)

1. Skinner DB, Ferguson MK, Soriano A, Little AG, Staszak RN. Selection of operation for esophageal cancer based on staging. Ann Surg 1986; 204: 391-401.
2. Patil P, Redker A, Patel SG et al. Prognosis of operable squamous cell carcinoma of the esophagus. Cancer 1993; 72: 20-24.
3. Nishihara T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998; 175: 47-51.
4. Bhansali MS, Fujita H, Kakegawa T et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg 1997; 21: 275-281.
5. Wang LS, Chi Kh, Hu Mh, Fahn HJ, Huang Mh. Management for patients with advanced T4 epidermoid carcinoma of the esophagus. J Surg Oncol 1996; 62: 22-29.
6. Chung SCS, Stuart RC. Li AKC. Surgical therapy for squamous-cell carcinoma of the esophagus. Lancet 1994; 343: 521-524.
7. Forastiere AA, Orringer MB, Tamayo CP et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 1990; 8: 119-127.
8. Kelsen DP, Ilson Dh. Chemotherapy and combined-modality therapy for esophageal cancer. Chest 1995; 107: s224-s232.
9. Ancona E, Ruol A, Castoro C et al. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell thoracic esophagus. Ann Surg 1997; 226: 714-724.
10. Cooper JS,Guo MD, Herskovic A et al. Chemotherapy of locally advanced esophageal cancer. JAMA 1999; 281: 1623-1627.
11. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch Surg 1992; 127: 1446-1450.
12. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984.
13. Kawahara K, Maekawa T, Okabayashi K et al. The number of lymph node metastases influences survival in esophageal cancer. J Surg Oncol 1998; 67: 160-163.
14. Skinner DB, Dowlatshahi KD, Demeester TR, Potentially curable cancer of the esophagus. Cancer 1982; 50: 2571-2575.
15. Natsugoe S, Mueller J, Stein H, Feith M, Hofler H, Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma. Cancer 1998; 83: 858-866.
16. Izbicki JR, Hosch SB, Pichlmeier U et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337: 1188-1194.
17. Japanese Society for Esophageal Disease. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, 9th edn. Tokyo: Kanehara Ltd, 1999.
18. Takubo K. Pathology of the Esophagus. Tokyo: Educa, 1999.
19. Moran RG. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer 1989; 63: 1008-1012.
20. Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer 1989; 63: 995-1007.
21. Hayashi K, Ide H, Shinoda M, Fukushima M. A phase II study of cisplatin and 5-fluorouracil plus leucovorin for squamous cell carcinoma of the esophagus. Cancer Res Ther Control 1993; 3: 115-119.
22. Ide H, Nakamura T, Hayashi K, Eguchi R, Tanigawa K, Ota M. Neoadjuvant chemotherapy with cisplatinum/5-fluorouracil/low-dose leucovorin for advanced squamous cell carcinoma of the esophagus. Semin Surg Oncol 1997; 13: 263-269.
23. Siewert JR, Holscher Ah, Dittler HJ. Preoperative staging and risk analysis in esophageal carcinoma. Hepato-Gastroenterology 1990; 37: 382-387.
24. Dittler HJ, Siewert JR. Role of endoscopic ultrasonography in esophageal carcinoma. Endoscopy 1993; 25: 156-161.
25. Peters Jh, Hoeft SF, Heimbucher J et al. Selection of patients for curative or palliative resection of esophageal cancer based on preoperative endoscopic ultrasonography. Arch Surg 1994; 129: 534-539.
26. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
27. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 1994; 54: 3718-3722.
28. Sarbia M, Stahl M, Fink U, Willers R, Seeber G, Gabbert HE. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998; 4: 2991-2997.
29. Rigberg DA, Kim FS, Blinman TA et al. p21 expression is increased by irradiation in esophageal squamous cell carcinoma. J Surg Res 1998: 76: 137-142.
30. Sarbia M, Stahl M, Fink U et al. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer (Pred Oncol) 1999; 84: 86-91.
31. Becker K, Fumagalli U, Mueller JD, Fink U, Siewert JR, Heinz H. Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma. Cancer 1999; 85: 1484-1148.